2 most recent filings and news items mentioning ODTX. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/ODTX/news?limit=20"
Pull ODTX filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayOdyssey Therapeutics, Inc. issued a corporate presentation outlining business strategy and future clinical developments. This update provides investors with insights into the company's developmental pipeline and regulatory outlook.
View filing at SEC.gov →Odyssey Therapeutics reported positive clinical proof-of-concept data for OD-001, its oral RIPK2 inhibitor, showing 27% clinical remission and 61% clinical response in moderate-to-severe ulcerative colitis patients. The company closed a $314.8M IPO and has $464M in cash expected
View filing at SEC.gov →